Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

被引：1

作者：

Johnson, Nathalie A. ^{[1
]}

Lavie, David ^{[2
]}

Borchmann, Peter ^{[3
]}

Gregory, Gareth P. ^{[4
]}

Herrera, Alex F. ^{[5
]}

Minuk, Leonard ^{[6
,7
]}

Vucinic, Vladan ^{[8
]}

Armand, Philippe ^{[9
]}

Avigdor, Abraham ^{[10
]}

Gasiorowski, Robin ^{[11
]}

Herishanu, Yair ^{[12
]}

Keane, Colm ^{[13
]}

Kuruvilla, John ^{[14
]}

Palcza, John ^{[15
]}

Pillai, Pallavi ^{[15
]}

Nahar, Akash ^{[15
]}

Timmerman, John ^{[16
]}

机构：

[1] Jewish Gen Hosp, Montreal, PQ, Canada

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Univ Klinikum Koeln AOER, Cologne, Germany

[4] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia

[5] City Hope Natl Med Ctr, Duarte, CA USA

[6] CancerCare Manitoba, Winnipeg, MB, Canada

[7] Univ Manitoba, Winnipeg, MB, Canada

[8] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Chaim Sheba Med Ctr, Ramat Gan, Israel

[11] Univ Sydney, Concord Hosp, Concord, Australia

[12] Sourasky Med Ctr, Tel Aviv, Israel

[13] Princess Alexandra Hosp, Brisbane, Qld, Australia

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166846

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6540 / 6542

页数：3

共 50 条

[41] KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
Armand, Philippe
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
Moskowitz, Craig H.
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie A.
Radford, John A.
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Gustafson, Eric
Zhang, Yinghua
Ricart, Alejandro Daniel
Balakumaran, Arun
Chen, Robert W.
BLOOD, 2016, 128 (22)
[43] A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda, Elena
Sukari, Ammar
Lakhani, Nehal J.
Patnaik, Amita
Lou, Yanyan
Im, Seock-Ah
Golan, Talia
Geva, Ravit
Wermke, Martin
De Miguel, Maria
Palcza, John
Jha, Sujata
Chaney, Marya F.
Healy, Jane Anne
Falchook, Gerald Steven
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087
Moskowitz, C.
Zinzani, P. L.
Fanale, M. A.
Armand, P.
Johnson, N.
Ribrag, V.
Radford, J.
von Tresckow, B.
Tomita, A.
Shipp, M. A.
Wang, Y.
Ricart, A. D.
Balakumaran, A.
Chen, R.
HAEMATOLOGICA, 2016, 101 : 319 - 319
[45] Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
Chen, Robert W.
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie
Ribrag, Vincent
Radford, John A.
Tomita, Akihiro
Shipp, Margaret Ann
Wang, Yang
Ricart, Alejandro Daniel
Balakumaran, Arun
Moskowitz, Craig H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46] Phase II Study of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 11
[47] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, Martin
Mous, Rogier
Clausen, Michael Roost
Johnson, Peter
Linton, Kim M.
Chamuleau, Martine E. D.
Lewis, David John
Balari, Anna Sureda
Cunningham, David
Oliveri, Roberto S.
Elliott, Brian
DeMarco, Dena
Azaryan, Ada
Chiu, Christopher
Li, Tommy
Chen, Kuo-mei
Ahmadi, Tahamtan
Lugtenburg, Pieternella J.
LANCET, 2021, 398 (10306): : 1157 - 1169
[48] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song
Quanli Gao
Huilai Zhang
Lei Fan
Jianfeng Zhou
Dehui Zou
Wei Li
Haiyan Yang
Ting Liu
Quanshun Wang
Fangfang Lv
Haiyi Guo
Liudi Yang
Rebecca Elstrom
Jane Huang
William Novotny
Vivian Wei
Jun Zhu
Leukemia, 2020, 34 : 533 - 542
[49] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Elstrom, Rebecca
Huang, Jane
Novotny, William
Wei, Vivian
Zhu, Jun
LEUKEMIA, 2020, 34 (02) : 533 - 542
[50] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
Godfrey, James
Mei, Matthew
Chen, Lu
Song, Joo Y.
Bedell, Victoria
Budde, L. Elizabeth
Armenian, Saro
Puverel, Sandrine
Nikolaenko, Liana
Chen, Robert
Daniels, Shari
Kennedy, Neena
Peters, Lacolle
Rosen, Steven T.
Forman, Stephen J.
Popplewell, Leslie L.
Kwak, Larry W.
Herrera, Alex F.
REVISTA CHILENA DE LITERATURA, 2024, (109): : 533 - 542

← 1 2 3 4 5 →